Loading...
Market
Story
FDA Approves Roche's HPV Self-Testing Kit on Wednesday, Including Self-Collection
May 15, 2024, 09:30 AM
Swiss drugmaker Roche announced on Wednesday that the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-testing kit. The self-sampling solution aims to address unequal access to screening that can put women at risk of cervical cancer. This approval provides an alternative to the traditional pelvic exam, potentially making it easier for women of color and those in rural and underserved communities to screen for HPV. The method involves self-collection for virus screening.
View original story
Similar markets
Below 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Above 75% • 25%
Significant increase in screenings • 33%
Moderate increase in screenings • 33%
No significant change in screenings • 34%
Very Satisfied • 25%
Satisfied • 25%
Neutral • 25%
Dissatisfied • 25%
High adoption by healthcare sector • 25%
High adoption by agricultural sector • 25%
Low adoption by healthcare sector • 25%
Low adoption by agricultural sector • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Less than 10% adoption • 25%
10% to 25% adoption • 25%
26% to 50% adoption • 25%
More than 50% adoption • 25%
< 10% adoption • 33%
10% to 30% adoption • 33%
> 30% adoption • 33%
Outperforms • 25%
Underperforms • 25%
Matches • 25%
Data Inconclusive • 25%
None • 33%
1-5 institutions • 33%
More than 5 institutions • 34%